To express the Sense of Congress with respect to safety of medication abortion and Federal preemption of State restrictions on dispensing medication abortion, and for other purposes.
- Bill Number
- H.R. 8734
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-05-11: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-06-26T08:07:08Z
AI-Generated Summary
Summary of H.R. 8734 (119th Congress)
Purpose
This bill expresses the "Sense of Congress"—a non-binding statement of congressional opinion—affirming the safety of medication abortion (abortion induced by FDA-approved drugs like mifepristone and misoprostol) and declaring that federal approval of these drugs overrides certain state restrictions on how they are dispensed.
Key Provisions
- Safety affirmation: Medication abortion is described as "extremely safe," with approval by the FDA Commissioner deemed appropriate based on scientific evidence under the Federal Food, Drug, and Cosmetic Act (FD&C Act, the main U.S. law regulating drugs).
- Federal preemption: FDA approval under the FD&C Act preempts (overrides) state laws that:
- Require medication abortion to be dispensed in person by a health care practitioner.
- Prohibit or restrict prescribing or dispensing medication abortion via telehealth (remote medical consultations using phone or video).
Significant Changes to Existing Law
- No direct changes, as this is a non-binding resolution without enforceable mandates.
- It signals Congress's view that FDA drug approvals automatically preempt specific state rules on dispensing medication abortion, potentially influencing future court interpretations of federal preemption under the Supremacy Clause of the U.S. Constitution.
Potential Impacts
- Citizens: Could expand access to medication abortion through telehealth, especially in states with in-person requirements, benefiting those in rural or restrictive areas.
- Government agencies: Reinforces FDA's authority; may guide FDA enforcement or litigation strategies.
- State governments: Challenges state-level restrictions post-Dobbs v. Jackson (2022 Supreme Court decision overturning federal abortion right), potentially leading to legal conflicts.
- No direct international relations impact.
Main Stakeholders
- Patients: Primarily women seeking medication abortion.
- Healthcare providers: Doctors and clinics using telehealth for prescriptions.
- Federal agencies: FDA (drug regulation).
- State governments: Regulators enforcing abortion dispensing rules.
- Pharmacies: Involved in dispensing the drugs.
Notable Legal, Constitutional, or Political Implications
- Legal: Asserts broad federal preemption doctrine, where federal drug approvals supersede conflicting state rules; could be cited in lawsuits against state laws.
- Constitutional: Touches on federalism (balance of federal vs. state power) without creating new rights or mandates.
- Political: Introduced by Democrats; reflects ongoing debates over abortion access after state-level restrictions increased following Dobbs. As a "sense" resolution, it has symbolic weight but limited immediate effect unless influencing legislation or judiciary.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (21)
Rep. Fletcher, Lizzie [D-TX-7], Rep. Vasquez, Gabe [D-NM-2], Rep. Chu, Judy [D-CA-28], Rep. Ross, Deborah K. [D-NC-2], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Titus, Dina [D-NV-1], Rep. Ansari, Yassamin [D-AZ-3], Rep. Huffman, Jared [D-CA-2], Rep. Larson, John B. [D-CT-1], Rep. Nadler, Jerrold [D-NY-12], Rep. Golden, Jared F. [D-ME-2], Rep. Walkinshaw, James R. [D-VA-11], Rep. Takano, Mark [D-CA-39], Rep. Garamendi, John [D-CA-8], Rep. McCollum, Betty [D-MN-4], Rep. Bonamici, Suzanne [D-OR-1], Rep. Moulton, Seth [D-MA-6], Rep. Simon, Lateefah [D-CA-12], Rep. Williams, Nikema [D-GA-5], Rep. Johnson, Henry C. "Hank" [D-GA-4], Rep. Bynum, Janelle S. [D-OR-5]
Recent Actions
- 2026-05-11: Referred to the House Committee on Energy and Commerce.
- 2026-05-11: Introduced in House
- 2026-05-11: Introduced in House
Bill Versions
- To express the Sense of Congress with respect to safety of medication abortion and Federal preemption of State restrictions on dispensing medication abortion, and for other purposes. — issued 2026-05-11 — PDF (2 pages)